A message about employment scams: Please note that Prime Medicine does not reach out to job applicants via social media and messaging platforms such as Facebook, Instagram, Skype, or WhatsApp. The only email domain we use for official business is @primemedicine.com, and our employees will never use alternate email addresses to contact candidates. Our team members will never request personal financial information or identification details, including bank account, social security, or driver’s license numbers. Additionally, we will not charge any fees, mail checks for equipment, nor ask you to make purchases as part of our hiring process.
Prime Medicine, Inc.
Biotechnology Research
Cambridge, Massachusetts 16,911 followers
Delivering on the promise of Prime Editing
About us
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
- Website
-
http://www.primemedicine.com
External link for Prime Medicine, Inc.
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Public Company
- Founded
- 2019
- Specialties
- Gene Editing
Locations
-
Primary
21 Erie St
Cambridge, Massachusetts 02139, US
Employees at Prime Medicine, Inc.
Updates
-
Prime recently celebrated #PrideMonth with vibrant rainbow leis, flags, pins and delicious cookies. We enjoyed an afternoon filled with laughter as we celebrated love and diversity. We’re keeping the celebration going with an internal Prime Pride Anthems playlist featuring our favorite LGBTQIA+ artists and songs that embody the spirit of this month. Happy Pride, everyone! 🏳️🌈
-
Listen below as CEO Keith Gottesdiener shares insight into his career trajectory, from a practicing physician to chief executive officer, on the latest episode of SSI Strategy’s The Emerging Biotech Leader podcast!
In the latest episode of the Emerging Biotech Leader podcast, our hosts Kimberly F. Kushner & Ramin Farhood sit down with Keith Gottesdiener, President and CEO of Prime Medicine. Keith shares his unique career journey that took him from treating patients as a physician to leading cutting-edge biotech companies. Hear his first-hand perspective on: 💼 Transitioning from academia to the corporate world 💡 Embracing an entrepreneurial mindset as CEO 👥 Building high-performing teams aligned with the company vision Listen now for an inside look at redefining career roles and steering ambitious biotech ventures towards success. https://lnkd.in/dZaiBUwF
-
We are excited to see new research from Prime co-founder David R. Liu's lab in Nature Portfolio Biomedical Engineering, detailing work on the development of the eePASSIGE system, which uses evolved and engineered recombinases and Prime Editing to integrate large gene-sized #DNA cargoes into the mammalian genome in an efficient, precise and targeted manner. This proprietary approach further increases the versatility of Prime Editing and broadens the range of permanent genomic edits that Prime Editing can make to treat disease. Congratulations to the team on this important publication!
-
We are pleased to share members of management will participate in healthcare conferences hosted by Jefferies and Goldman Sachs in June. Details below. https://lnkd.in/gU5amPjc
-
Prime CFO Allan Reine will participate in a fireside chat at an H.C. Wainwright conference this month. Details below. https://lnkd.in/e3VCszF2
-
#TIDES2024 kicks off tomorrow here in Boston, and we look forward to presentations from several Prime team members throughout the week! Join us live at TIDES and learn more below.
-
The American Society of Gene & Cell Therapy Outstanding Achievement Award, the Society's highest honor, recognizes a member who has achieved a pioneering research success, specific high-impact accomplishment, or a lifetime of significant contributions to the field of gene and cell therapy. We are thrilled to congratulate David R. Liu on being this year's recipient. Congratulations, David, on this well-deserved honor!
-
We are pleased to report new preclinical data demonstrating the ability of PM359 to correct a common disease-causing mutation of CGD. Jennifer Gori will present these findings at #ASGCT2024 this evening. Full details below. https://lnkd.in/euUeTEjb
-
Prime team members are in Baltimore this week to present data at #ASGCT2024. We invite you to join us live onsite or to listen in virtually to these presentations. Thank you to everyone at American Society of Gene & Cell Therapy for their work to curate another valuable event!